| Mark Schneyer, MD | |
|
23 Crossroads Dr Ste 400, Owings Mills, MD 21117-5490 | |
| (410) 356-2626 | |
| Not Available |
| Full Name | Mark Schneyer |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 13 Years |
| Location | 23 Crossroads Dr Ste 400, Owings Mills, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1952523128 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | D71919 (Maryland) | Primary |
| 390200000X | Student In An Organized Health Care Education/training Program | 0116018375 (Virginia) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Greater Baltimore Medical Center | Baltimore, MD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Centers For Advanced Ent Care Llc | 1658647359 | 125 |
News Archive
Researchers at Okayama University have uncovered a potential new therapeutic target for invasive bladder cancer. The GTP hydrolysing enzyme (GTPase), called Dynamin2, facilitates the rapid invasion of cancer into surrounding tissues; inhibiting its activity could limit the progression of bladder cancer.
Takeda Pharmaceutical Company Limited and Affymax, Inc. today announced their agreement to suspend co-development of Hematide to treat chemotherapy-induced anemia and to focus all development efforts for Hematide on the treatment of chronic kidney disease related anemia.
Researchers in the U.S. say that obese men have lower levels of a protein used to screen for prostate cancer risk, and doctors should take weight into account when determining a man's risk.
Biologists are used to thinking about DNA sequences as a string of letters (A, C, G, T) that happens to be arranged in an elegant double helix. But DNA also has mechanical properties that affect how genes are turned on or off, say researchers at the UC Davis Genome Center.
› Verified 8 days ago
| Entity Name | Greater Baltimore Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891855763 PECOS PAC ID: 1759276975 Enrollment ID: O20040217000852 |
News Archive
Researchers at Okayama University have uncovered a potential new therapeutic target for invasive bladder cancer. The GTP hydrolysing enzyme (GTPase), called Dynamin2, facilitates the rapid invasion of cancer into surrounding tissues; inhibiting its activity could limit the progression of bladder cancer.
Takeda Pharmaceutical Company Limited and Affymax, Inc. today announced their agreement to suspend co-development of Hematide to treat chemotherapy-induced anemia and to focus all development efforts for Hematide on the treatment of chronic kidney disease related anemia.
Researchers in the U.S. say that obese men have lower levels of a protein used to screen for prostate cancer risk, and doctors should take weight into account when determining a man's risk.
Biologists are used to thinking about DNA sequences as a string of letters (A, C, G, T) that happens to be arranged in an elegant double helix. But DNA also has mechanical properties that affect how genes are turned on or off, say researchers at the UC Davis Genome Center.
› Verified 8 days ago
| Entity Name | Centers For Advanced Ent Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447781620 PECOS PAC ID: 1658647359 Enrollment ID: O20171025001018 |
News Archive
Researchers at Okayama University have uncovered a potential new therapeutic target for invasive bladder cancer. The GTP hydrolysing enzyme (GTPase), called Dynamin2, facilitates the rapid invasion of cancer into surrounding tissues; inhibiting its activity could limit the progression of bladder cancer.
Takeda Pharmaceutical Company Limited and Affymax, Inc. today announced their agreement to suspend co-development of Hematide to treat chemotherapy-induced anemia and to focus all development efforts for Hematide on the treatment of chronic kidney disease related anemia.
Researchers in the U.S. say that obese men have lower levels of a protein used to screen for prostate cancer risk, and doctors should take weight into account when determining a man's risk.
Biologists are used to thinking about DNA sequences as a string of letters (A, C, G, T) that happens to be arranged in an elegant double helix. But DNA also has mechanical properties that affect how genes are turned on or off, say researchers at the UC Davis Genome Center.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mark Schneyer, MD 23 Crossroads Dr Ste 400, Owings Mills, MD 21117-5490 Ph: (410) 356-2626 | Mark Schneyer, MD 23 Crossroads Dr Ste 400, Owings Mills, MD 21117-5490 Ph: (410) 356-2626 |
News Archive
Researchers at Okayama University have uncovered a potential new therapeutic target for invasive bladder cancer. The GTP hydrolysing enzyme (GTPase), called Dynamin2, facilitates the rapid invasion of cancer into surrounding tissues; inhibiting its activity could limit the progression of bladder cancer.
Takeda Pharmaceutical Company Limited and Affymax, Inc. today announced their agreement to suspend co-development of Hematide to treat chemotherapy-induced anemia and to focus all development efforts for Hematide on the treatment of chronic kidney disease related anemia.
Researchers in the U.S. say that obese men have lower levels of a protein used to screen for prostate cancer risk, and doctors should take weight into account when determining a man's risk.
Biologists are used to thinking about DNA sequences as a string of letters (A, C, G, T) that happens to be arranged in an elegant double helix. But DNA also has mechanical properties that affect how genes are turned on or off, say researchers at the UC Davis Genome Center.
› Verified 8 days ago
Yemeng Lu-myers, M.D., M.P.H Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 23 Crossroads Dr Ste 400, Owings Mills, MD 21117 Phone: 410-356-2626 Fax: 410-356-8945 | |
Mark A Mashburn, M.D. Otolaryngology Medicare: Medicare Enrolled Practice Location: 23 Crossroads Dr, Suite 400, Owings Mills, MD 21117 Phone: 410-356-2626 Fax: 410-356-8945 | |
Kevin Connolly, Otolaryngology Medicare: Medicare Enrolled Practice Location: 23 Crossroads Dr Ste 400, Owings Mills, MD 21117 Phone: 410-356-2626 | |
Dr. Douglas C Mccorkle, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 10 Crossroads Drive, Suite 100, Owings Mills, MD 21117 Phone: 410-363-7172 Fax: 410-363-7188 | |
Michael David Weiss, M.D. Otolaryngology Medicare: Medicare Enrolled Practice Location: 23 Crossroads Dr, Suite 400, Owings Mills, MD 21117 Phone: 410-356-2626 | |
Tam N Nguyen, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 23 Crossroads Dr, Suite 400, Owings Mills, MD 21117 Phone: 410-356-2626 Fax: 410-356-8945 | |
Daniel Victor Santos, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 23 Crossroads Dr, Suite 400, Owings Mills, MD 21117 Phone: 410-356-2626 |